TY  - CHAP
AU  - Suree Jianmongkol
ED  - Hilal Arnouk
ED  - Bassam Abdul Rasool Hassan
Y1  - 2021-01-14
PY  - 2021
T1  - Overcoming P-Glycoprotein-Mediated Doxorubicin Resistance
N2  - Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin’s drug resistance and critical side effects.
BT  - Advances in Precision Medicine Oncology
SP  - Ch. 11
UR  - https://doi.org/10.5772/intechopen.95553
DO  - 10.5772/intechopen.95553
SN  - 978-1-83968-868-3
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-26
ER  -